1. Home
  2. TORO vs CGEN Comparison

TORO vs CGEN Comparison

Compare TORO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$4.97

Market Cap

173.8M

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.37

Market Cap

191.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
CGEN
Founded
2022
1993
Country
Cyprus
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.8M
191.1M
IPO Year
2022
2001

Fundamental Metrics

Financial Performance
Metric
TORO
CGEN
Price
$4.97
$2.37
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
33.7K
301.9K
Earning Date
04-15-2026
05-18-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$1.30
52 Week High
$8.50
$3.24

Technical Indicators

Market Signals
Indicator
TORO
CGEN
Relative Strength Index (RSI) 45.83 58.87
Support Level $4.89 $1.48
Resistance Level $5.85 $3.05
Average True Range (ATR) 0.28 0.09
MACD 0.00 0.06
Stochastic Oscillator 36.99 97.95

Price Performance

Historical Comparison
TORO
CGEN

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: